An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects.

Trial Profile

An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs Eletriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 19 Aug 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top